PURPOSE: To evaluate the prevalence of Metabolic Syndrome (MS) in an acute coronary syndrome (ACS) population with newly recognized glucometabolic abnormalities and to assess its impact on glucidic profile evolution.
METHODS: Prospective study of 89 patients, consecutively admitted for ACS, in a single coronary care unit, from June/05 to June/06, with newly recognized glucometabolic abnormality based on oral glucose tolerance test (OGTT). Patients started on antidiabetic treatment during hospitalisation were excluded. MS was diagnosed using the International Diabetes Federation (IDF) definition. Follow-up was carried out 12 months after hospital discharge and patients were challenged with OGTT.
RESULTS: The most common metabolic disorders were central obesity (84.7%), hypertension (68.8%) and fasting hyperglycemia (64.0%). MS was diagnosed in 60.5% of patients. MS group had more coronary stenosis, higher levels of Apolipoprotein B (ApoB) and higher body mass index (BMI) (table 1). Spearman correlation coefficients were used to identify factors associated with MS. We found a significant positive correlation with number of coronary stenosis (NCS) (r = 0.336, p = 0.010), BMI (r = 0.301, p = 0.010), ApoB (r = 0.262, p = 0.028) and ApoB/ApoA (r = 0.399, p = 0.001). MS showed neither correlation with evolution of glucidic profile nor with cardiovascular events.
CONCLUSION: MS was highly prevalent in ACS patients with glucometabolic abnormalities and seemed to be associated with more severe coronary stenosis and higher ApoB levels. However, MS was unable to predict a specific profile evolution or the occurance of cardiovascular events.
CLINICAL IMPLICATIONS: The metabolic syndrome helps identifying people at higher risk of developing diabetes. However it is still unknown if MS can predict the evolution of newly recognized glucometabolic abnormalities.
DISCLOSURE: Natalia Antonio, No Financial Disclosure Information; No Product/Research Disclosure Information